“…The results presented here support an important role for the Gpx4-dependent glutathione metabolic pathway in the regulation of Mtb-induced necrosis and implicate this process as a potential target for host-directed therapy of tuberculosis. In this regard, glutathione itself has been shown to regulate Mtb infection outcomes in several murine experimental and clinical TB studies ( Cao et al, 2021 ; Guerra et al, 2011 ; Morris et al, 2013 ; Safe et al, 2020a ; Safe et al, 2020b ; To et al, 2021 ; Venketaraman et al, 2008 ; Venketaraman et al, 2006 ), but to the best of our knowledge glutathione administration, in its reduced form, has never been tested in a formal clinical trial in TB patients. In terms of Gpx4 itself, any HDT specifically targeting this enzyme would have to increase rather than inhibit its activity to be an effective therapy.…”